Correspondence to: Professor Gilbert R Thompson, Metabolic Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK; [email protected] _________________________ D yslipidaemia is a preferable term to hyperlipidaemia because it includes risk factors such as a decreased concentration of high density lipoprotein (HDL) cholesterol as well as qualitative changes in low de...

HIV infection, as well as its treatment with highly active retroviral therapy (HAART), is associated with a number of metabolic abnormalities such as insulin resistance, glucose intolerance and dyslipidaemia. The aim of this descriptive cross sectional study was to describe the prevalence of diabetes, impaired fasting glucose, dyslipidaemia and obesity among patients with HIV or AIDS who were f...

Hyperglycaemia is the major risk factor for the development of complications in both Type I and Type II diabetes; however, there is growing evidence from several clinical trials that dyslipidaemia, including hypertriglyceridaemia, is a significant and independent risk factor for diabetic complications. In this paper, we propose that chemical modification of proteins by lipids may be a underlyin...

DYSLIPIDAEMIA IN ESTABLISHED AND FUTURE PATIENTS WITH RA Several investigators have indeed demonstrated dyslipidaemia, definedashigher total cholesterol and/or triglycerides and/or lower high-density lipoprotein (HDL) cholesterol levels in comparison to control subjects, in RA and thisappears tobethe consequence of systemic release of inflammatory cytokines such as tumour necrosis factor (TNF)a...

BACKGROUND/OBJECTIVES Cardiovascular disease is a major cause of morbidity and mortality among patients with chronic kidney disease, and accounts for 50% of all deaths in them. Dyslipidaemia does not only accelerate atherosclerosis in these patients but also progresses the renal disease. This study therefore set to investigate the pattern of lipid profile in pre-dialysis chronic kidney disease ...

Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogeni...

BACKGROUND The use of HIV protease inhibitors (PIs) as a component of combination antiretroviral therapy in HIV-infected patients has been associated with dyslipidaemia, but its significance as a risk factor for cardiovascular disease is unclear. Endothelial dysfunction is an early phase of atherogenesis that may be assessed non-invasively with ultrasonography in vivo. AIM To evaluate vascula...

BACKGROUND There is little information regarding the prevalence and management of dyslipidaemia in Switzerland. DESIGN Cross-sectional population-based study of 3238 women and 2846 men aged 35-75. METHODS Dyslipidaemia prevalence, treatment and control were defined according to PROCAM guidelines adapted to Switzerland. RESULTS About 29% of the overall sample presented with dyslipidaemia, ...